Article
Rationale and design of the BRAVERY study (EPOC1701): a multicentre phase II study of eribulin in patients with BRAF V600E mutant metastatic colorectal cancer.
ESMO open - 1 Jan 2019
Masuishi Toshiki, Taniguchi Hiroya, Kotani Daisuke, Bando Hideaki, Komatsu Yoshito, Shinozaki Eiji, Nakajima Takako Eguchi, Satoh Taroh, Nishina Tomohiro, Esaki Taito, Wakabayashi Masashi, Nomura Shogo, Takahashi Koji, Ono Hiromi, Hirano Nami, Fujishiro Noriko, Fuse Nozomu, Sato Akihiro, Ohtsu Atsushi, Yoshino Takayuki
Abstract excerpt
Background: BRAF V600E mutations are associated with aggressive biology and limited response to standard chemotherapy, especially during second-line and beyond therapies. BRAF V600E mutant and wild-type colorectal cancers (CRCs) differ in their expression profiles, and preclinical evidence suggests that microtubule inhibitors have an antitumour effect on xenograft models of BRAF V600E mutant CRCs. Eribulin has...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.